KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review

Date: March 11, 2014
Pages: 20
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: KC62950F7CEEN
Leaflet:

Download PDF Leaflet

KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review
KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

KAEL-GemVax Co.,Ltd. (KAEL-GemVax) is a manufacturer of pharmaceutical products. The company develops and commercializes vaccines for the treatment of cancer using its technology. Its pipeline products include Telovac indicated for pancreatic cancer; Lucavax indicated for lung cancer, GV1001 for stimulating the immune response; Hormonal modulators indicated for Benign Prostate Hyperplasia and anti-inflammation vaccines indicated for cancer cachexia. It partners with Orion Clinical Services, Lonza, Elaiapharm, Penn Pharma, Cancer Research UK, Seoul National University, Hanyang University, National Cancer Center and KAIST. It has 87 patents registered in 34 countries.

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

KAEL-GemVax Co., Ltd. - Key Facts
KAEL-GemVax Co., Ltd. - Key Employees
KAEL-GemVax Co., Ltd. - Major Products and Services
KAEL-GemVax Co., Ltd. - Pharmaceutical Pipeline Products Data
KAEL-GemVax Co., Ltd., Pipeline Products by Therapy Area
KAEL-GemVax Co., Ltd., Pipeline Products by Development Phase
KAEL-GemVax Co., Ltd. - History
KAEL-GemVax Co., Ltd. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

KAEL-GemVax Co., Ltd. - Business Description
KAEL-GemVax Co., Ltd. - SWOT Analysis
SWOT Analysis - Overview
KAEL-GemVax Co., Ltd. - Strengths
Strength - Robust Research and Development Capabilities
Strength - Business Collaborations
Strength - Strong Patent Portfolio
KAEL-GemVax Co., Ltd. - Weaknesses
Weakness - Lack of Sufficient Funds
KAEL-GemVax Co., Ltd. - Opportunities
Opportunity - Market Potential:Pancreatic Cancer
Opportunity - Demographic Trends
Opportunity - Pipeline Products
KAEL-GemVax Co., Ltd. - Threats
Threat - Uncertain R&D Outcomes
Threat - Government Regulations
Threat - Intense Competition
KAEL-GemVax Co., Ltd. - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
KAEL-GemVax Co., Ltd., Recent Deals Summary

SECTION 4 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

KAEL-GemVax Co., Ltd., Key Facts
KAEL-GemVax Co., Ltd., Key Employees
KAEL-GemVax Co., Ltd., Major Products and Services
KAEL-GemVax Co., Ltd., Number of Pipeline Products by Therapy Area
KAEL-GemVax Co., Ltd., Number of Pipeline Products by Development Stage
KAEL-GemVax Co., Ltd., Pipeline Products By Therapy Area and Development Phase
KAEL-GemVax Co., Ltd., History
KAEL-GemVax Co., Ltd., Key Competitors
KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
KAEL-GemVax Co., Ltd., Recent Deals Summary

LIST OF FIGURES

KAEL-GemVax Co., Ltd., Pipeline Products by Therapy Area
KAEL-GemVax Co., Ltd., Pipeline Products by Development Phase
KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
KAEL-GemVax Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Skip to top


Ask Your Question

KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: